Shares of Ardelyx (ARDX) have gained 6.3% over the past four weeks to close the last trading session at $9.27, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.50 indicates a potential upside of 34.8%.The average comprises seven short-term price targets ranging from a low of $11 to a high of $15, with a standard deviation of $1.55. While the lowest estimate indicates an incre ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Ardelyx (ARDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnin ...

The Russell 2000 index aims to track and provide exposure to small-cap U.S. equities. It is an ETF that experiences a large amount of trading volume and is great for investors looking for exposure to smaller companies without the risk of investing in small-cap companies directly.The stocks chosen below are within the iShares Russell 2000 ETF (NYSEARCA:IWM), which tracks the Russell 2000 Index and has approximately $59 billion in assets under management and over 40 million in average daily volume. The compan ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Ardelyx (ARDX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Ardelyx is a member of our Medical group, which includes 1073 different companies and currently sits at #7 in ...

In general, high-growth stocks  and sleeper stocks under $15 are associated with valuation concerns. Let’s forget inflated giants and overhyped darlings. Today, the article reveals three hidden gems. The three sleeper stocks under $15 I’ll be pointing out today are audacious innovators and may erupt like financial volcanoes by 2029.The first one, a fintech, is shaking up the industry with its revolutionary app, offering everything from student loan refinancing to investing. It capitalizes on consumers’ pref ...

Gilnature/iStock via Getty Images My previous coverage on Ardelyx (NASDAQ:ARDX), now a $2 billion cap biopharmaceutical, came during FDA approval of tenapanor’s second indication. The first and only phosphate absorption inhibitor is now sold as XPHOZAH in combination with phosphate binders to treat hyperphosphatemia in adults with end-stage renal disease (ESRD) on dialysis, as well as IBSRELA for irritable bowel syndrome with constipation. Since publication, shares skyrocketed more than 230% as the comp ...

Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company before it releases positive results. But on the flip side, a single negative press release could send a stock tumbling with biotech stocks being so volatile. Overall, it is an industry that average investors should tread through lightly, but for investors looking for dramatic growth potential, the biotech industry i ...

WALTHAM, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on January 10, 2024, the compensation committee of the company's board of directors granted two new non-executive employees options to purchase an aggregate of 23,580 shares of the company's common stock, and granted three new non-executive e ...

Investors tend to be attracted to stocks that trade at a cheap price due to the fact that they offer the possibility of great returns for not a large amount of capital invested. Small-cap companies typically trade at a lower price compared to larger companies. Investors should be aware that stocks that trade at a cheap rate, such as below $10 per share, are inherently riskier than stocks with a strong financial position and great reputation. Cheap companies have a much higher chance of wild swings in their ...